| Dr Thomas J Demaro, DO | |
|
5823 Apple Valley Dr, Knoxville, TN 37924-3115 | |
| (561) 334-3774 | |
| Not Available |
| Full Name | Dr Thomas J Demaro |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 21 Years |
| Location | 5823 Apple Valley Dr, Knoxville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053350363 | NPI | - | NPPES |
| 009935562 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 18271 (Florida) | Secondary |
| 207Q00000X | Family Medicine | 1927 (Tennessee) | Secondary |
| 207P00000X | Emergency Medicine | 1927 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Homestead Hospital | Homestead, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Paragon Contracting Services Llc | 3971417825 | 264 |
News Archive
Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China's vaccine is the first one to proceed to phase III human trials.
Rare cells can be identified within mixed cell populations with near perfect accuracy using a detection technique devised by research teams led by Robert Wieder, MD, PhD, at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School and Rajan Kumar, MD, PhD, at Genome Data Systems in Hamilton, N.J. This technique may facilitate cancer diagnosis, which often relies on the detection of rare cancerous cells in tiny amounts of biopsy tissue or fluid.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Scientists at University College Dublin, Ireland, have identified a genetic alteration which causes a child to be born with no eyes - a condition called anophthalmia.
› Verified 4 days ago
| Entity Name | Paragon Contracting Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225071459 PECOS PAC ID: 3971417825 Enrollment ID: O20041207001148 |
News Archive
Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China's vaccine is the first one to proceed to phase III human trials.
Rare cells can be identified within mixed cell populations with near perfect accuracy using a detection technique devised by research teams led by Robert Wieder, MD, PhD, at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School and Rajan Kumar, MD, PhD, at Genome Data Systems in Hamilton, N.J. This technique may facilitate cancer diagnosis, which often relies on the detection of rare cancerous cells in tiny amounts of biopsy tissue or fluid.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Scientists at University College Dublin, Ireland, have identified a genetic alteration which causes a child to be born with no eyes - a condition called anophthalmia.
› Verified 4 days ago
| Entity Name | Shi Keys Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952903536 PECOS PAC ID: 2163835513 Enrollment ID: O20210105000345 |
News Archive
Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China's vaccine is the first one to proceed to phase III human trials.
Rare cells can be identified within mixed cell populations with near perfect accuracy using a detection technique devised by research teams led by Robert Wieder, MD, PhD, at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School and Rajan Kumar, MD, PhD, at Genome Data Systems in Hamilton, N.J. This technique may facilitate cancer diagnosis, which often relies on the detection of rare cancerous cells in tiny amounts of biopsy tissue or fluid.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Scientists at University College Dublin, Ireland, have identified a genetic alteration which causes a child to be born with no eyes - a condition called anophthalmia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas J Demaro, DO 5823 Apple Valley Dr, Knoxville, TN 37924-3115 Ph: (561) 334-3774 | Dr Thomas J Demaro, DO 5823 Apple Valley Dr, Knoxville, TN 37924-3115 Ph: (561) 334-3774 |
News Archive
Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China's vaccine is the first one to proceed to phase III human trials.
Rare cells can be identified within mixed cell populations with near perfect accuracy using a detection technique devised by research teams led by Robert Wieder, MD, PhD, at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School and Rajan Kumar, MD, PhD, at Genome Data Systems in Hamilton, N.J. This technique may facilitate cancer diagnosis, which often relies on the detection of rare cancerous cells in tiny amounts of biopsy tissue or fluid.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Scientists at University College Dublin, Ireland, have identified a genetic alteration which causes a child to be born with no eyes - a condition called anophthalmia.
› Verified 4 days ago
Stephen Holtzclaw, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 265 Brookview Centre Way, Suite 400, Knoxville, TN 37919 Phone: 865-293-5310 | |
Dr. Robert Lembersky, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2018 W Clinch Ave, Knoxville, TN 37916 Phone: 865-541-8485 | |
Georganna Michelle Rosel, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, Knoxville, TN 37920 Phone: 865-305-9000 | |
Dr. Julie W Jeter, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy # U67, Knoxville, TN 37920 Phone: 865-305-9350 Fax: 865-305-8681 | |
Dr. Robert K. Dickson, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2018 W Clinch Ave, Knoxville, TN 37916 Phone: 865-541-8000 | |
Dr. Joseph Tucker Montgomery, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 528 Dixon Rd, Knoxville, TN 37934 Phone: 865-604-3476 Fax: 865-675-0833 |